Abstract: This small study reports on a non-pyrogenic response of five different Australian isolates of Coxiella burnetii (C. burnetii). They were all members of Genomic Group IV and obtained from three cases of acute human infection, one case of chronic human infection and one case of goat abortion. The guinea pigs infected with these isolates did not develop fever (temperature ≥ 40.0 • C), which is consistent with other members of this genomic group that were isolated from elsewhere in the world. In contrast, guinea pigs infected with the classical USA tick isolate, Nine Mile phase 1 (RSA 493) of Genomic Group I, experienced a four-day febrile period.
Introduction
Guinea pigs are an excellent small animal model of acute Q fever (infection with Coxiella burnetii or C. burnetii) in humans [1] [2] [3] . However, not all isolates of C. burnetii will cause fever (pyrogenicity) in guinea pigs. This feature of the bacterium appears to be related to the genomic group to which the isolate belongs, with group IV and VI known to be non-pyrogenic [4] .
Recent Australian isolates of C. burnetii belong to a unique subset of genomic group IV; however, most were isolated from patients with acute Q fever, many of whom had presented with fever [5] . The question investigated in this small study was whether a selection of these Australian isolates were pyrogenic in guinea pigs.
Materials and Methods

Animal Ethics
This study was approved by the Australian Rickettsial Reference Laboratory Animal Care and Ethics Committee (ACEC/010). All experimental works were performed in a biosafety level 3 laboratory at the Department of Microbiology, John Hunter Hospital, Newcastle, New South Wales, Australia.
Coxiella Burnetii Isolates
Five Australian isolates of C. burnetii were selected for use in this study, with a range of molecular and epidemiological features (Table 1 ). All were members of genomic group IV, but represented three different genotypes (CbAu01, CbAu04 and CbAu06) according to a multi-locus variable number of tandem repeats (VNTR) analysis (MLVA). These genotypes were shown to be unique to Australia [5] .
There were four human isolates that came from three cases of acute infection (AuQ01, AuQ10 and AuQ43) and one case of chronic infection (AuQ04). There was also one isolate from an aborting goat (AuQ57), which was associated with a number of human cases [6] .
C. burnetii Nine Mile phase 1 (RSA493), originally obtained from a tick in the USA and belonging to Genomic Group I, was used as a positive control, as it was known to be pyrogenic in guinea pigs. Sterile cell culture medium (RPMI-1640) was used as a negative control. 
Culture and Quantification of C. burnetii in VERO Cell Line and Wild Mice
Vero cells were grown in 10ml RPMI (Gibco, Australia) supplemented with 10% new born calf serum (NBCS) (Gibco, Australia) and 1% L-glutamine (Gibco, Australia). The five C. burnetii isolates were inoculated into Vero cell monolayer and grown at 37 • C with 5% CO 2 for 14 days. The infected monolayer was removed by scrapping and each preparation inoculated intraperitoneally into a single outbred mouse. This was done to ensure that all C. burnetii cells were in phase 1 (virulent) for the later guinea pig infection [7] . Each infected mouse was euthanized seven days later and its enlarged spleen removed aseptically. Each spleen was separately homogenized in 5 mL of Hank's Balanced Salt Solution and the concentration of C. burnetii DNA measured by quantitative real-time PCR (qPCR) using an assay targeting the single-copy com1 gene [8] . Each spleen suspension was adjusted to contain between 10 6 and 10 7 C. burnetii per 0.2 mL.
Experimental Guinea Pig Infection
Outbred breeds of adult male guinea pigs were used in this study (n = 24). One week prior to the start of the experiment, an IPTT300 temperature transponder (Biomedic Data Systems, Inc., Seaford, DE, USA) was implanted into the sub-cutaneous tissue on the flank of each guinea pig.
Each guinea pig was anaesthetized with a 0.2 mL intramuscular injection of 9.5 mL of ketamine (100 mg/mL) and 0.5 mL of xylazine (100 mg/mL). Each anaesthetized guinea pig had 0.2 mL of the infected mouse spleen suspension introduced slowly into its nostrils via a fine-bore plastic Pasteur pipette. The guinea pigs inhaled the liquid slowly and the C. burnetii presumably entered the animals' lungs.
Monitoring Guinea Pig Temperature with Probe
Guinea pig temperatures were recorded daily for 21 days using an IPTT-300 Smart Probe held over the location of the subcutaneous temperature transponder in the guinea pig.
A temperature at or above 40 • C was defined as a fever and the guinea pig considered to be febrile. The experiment was terminated at day 21 post-infection by which time all guinea pig temperatures had returned to normal.
Results
The temperature changes in the 24 guinea pigs (grouped according to the isolate of C. burnetii used to infect them) are shown in the Figure 1 . The four guinea pigs given only Roswell Park Memorial Institute (RPMI) medium intranasally (negative controls) did not develop a fever at any stage. 
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Discussion
The best small animal model for studying Q fever is the guinea pig, as it develops a fever of limited duration, similar to infected humans [3] . However, not all isolates of C. burnetii are pyrogenic in the guinea pig. Studies of non-Australian isolates show that those from genomic groups IV and VI are non-pyrogenic [4] . This study has now demonstrated the same phenomenon of non-pyrogenicity in five Australian isolates, which all belong to genomic group IV, albeit to a unique subgroup. The four human isolates used in this study caused fever in the human patients from whom the bacteria were obtained. However, they did not cause fever in the guinea pigs. While the pathological basis for this difference is not known, there is a practical significance to it. When using guinea pigs to test new vaccines for use against Q fever and using abrogation of fever as a clinical indicator of vaccine success, it is necessary to use a challenge isolate of C. burnetii that causes fever in the non-immunized guinea pigs. On the basis of this small study it will not be possible to use Australian isolates of C. burnetii for The four guinea pigs given C. burnetii Nine Mile phase 1 (positive control), developed fever (40.6 ± 0.3) from days 8-11 after infection (four-day duration). None of the five Australian C. burnetii isolates, inoculated into 16 guinea pigs, resulted in fever (38.6 ± 1.0). They were all non-pyrogenic.
The best small animal model for studying Q fever is the guinea pig, as it develops a fever of limited duration, similar to infected humans [3] . However, not all isolates of C. burnetii are pyrogenic in the guinea pig. Studies of non-Australian isolates show that those from genomic groups IV and VI are non-pyrogenic [4] . This study has now demonstrated the same phenomenon of non-pyrogenicity in five Australian isolates, which all belong to genomic group IV, albeit to a unique subgroup. The four human isolates used in this study caused fever in the human patients from whom the bacteria were obtained. However, they did not cause fever in the guinea pigs. While the pathological basis for this difference is not known, there is a practical significance to it. When using guinea pigs to test new vaccines for use against Q fever and using abrogation of fever as a clinical indicator of vaccine success, it is necessary to use a challenge isolate of C. burnetii that causes fever in the non-immunized guinea pigs. On the basis of this small study it will not be possible to use Australian isolates of C. burnetii for challenge in Q fever vaccine studies, if abrogation of fever is used as a clinical marker of vaccine protection. It appears that the Nine Mile phase 1 isolate of C. burnetii is required for this purpose.
Conclusions
Australian isolates of C. burnetii do not cause fever in experimentally infected guinea pigs, confirming what has been shown in other genomic group IV isolates elsewhere in the world.
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